摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2-methyl-tetrahydro-furan-3-yl)-piperazine-1-carboxylic acid tert-butyl ester | 1147422-63-6

中文名称
——
中文别名
——
英文名称
4-(2-methyl-tetrahydro-furan-3-yl)-piperazine-1-carboxylic acid tert-butyl ester
英文别名
Tert-butyl 4-(2-methyloxolan-3-yl)piperazine-1-carboxylate
4-(2-methyl-tetrahydro-furan-3-yl)-piperazine-1-carboxylic acid tert-butyl ester化学式
CAS
1147422-63-6
化学式
C14H26N2O3
mdl
——
分子量
270.372
InChiKey
WIHVSPAIVACVNP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    19
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.93
  • 拓扑面积:
    42
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS
    申请人:Hancox Timothy Colin
    公开号:US20110021496A1
    公开(公告)日:2011-01-27
    Thienopyrimidines of formula (I) wherein W and R 1 to R 4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
    公式(I)中,W和R1至R4的定义如索权所述,其药学上可接受的盐是PI3K的抑制剂,并且选择性地作用于p110δ同工酶,该同工酶是一种Ia类PI3激酶,优于其他Ia类和Ib类激酶。这些化合物可用于治疗由PI3激酶引起的异常细胞生长、功能或行为所引起的疾病和障碍,如癌症、免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌功能障碍和神经系统障碍。
  • THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS
    申请人:F. Hoffmann-La Roche AG
    公开号:EP2205610A1
    公开(公告)日:2010-07-14
  • US8293735B2
    申请人:——
    公开号:US8293735B2
    公开(公告)日:2012-10-23
  • [EN] THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE THIÉNOPYRIMIDIÈNE COMME INHIBITEURS DE PI3K
    申请人:HOFFMANN LA ROCHE
    公开号:WO2009053715A1
    公开(公告)日:2009-04-30
    Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
查看更多